As a dialysis patient and peer coach, Caroline Wilkie knows how postdialysis fatigue and cramping can get in the way of socializing, work, or other responsibilities.
“A lot of us don’t plan things in advance because we never know how tired we’re going to be,” Wilkie said.
In dialysis patients with atrial fibrillation, the factor Xa inhibitor apixaban reduced the risk of major bleeding compared to warfarin in a nationwide sample, reports a study in Circulation.
Standard-dose apixaban is also associated with lower risks of thromboembolism and death compared to warfarin.
Imagine this scenario as a nephrologist.
The global burden of kidney diseases is much higher than commonly reported, according to a notice recently issued by the American Society of Nephrology (ASN), European Renal Association—European Dialysis and Transplant Association (ERA-EDTA), and International Society of Nephrology (ISN).
© Copyright 2019 American Society of Nephrology | All Rights Reserved | Website Policies | RSS
